Background Atrial fibrillation (AF) is the most prevalent arrhythmia worldwide and the main
cause of anticoagulation, being direct oral anticoagulants (DOAC) increasingly used in this …

Background Limited clinical data exist describing the use of direct oral anticoagulants
(DOACs) in patient with extreme body weight. Thus, the International Society of Thrombosis …

Direct oral anticoagulants (DOACs) are a favored treatment to prevent stroke in patients with
atrial fibrillation (AF). There are limited data concerning the efficacy and safety of DOACs in …

Highlights•Direct oral anticoagulants did not increase stroke or systemic embolism event
rate.•Direct oral anticoagulants had lower major bleeding rate than warfarin.•Direct oral …

Background: The International Society of Thrombosis and Haemostasis recommends
avoiding direct oral anticoagulants (DOACs) in morbidly obese patients with a body mass …

Introduction Due to fixed dosing of direct oral anticoagulants (DOACs), uncertainty exists
about their efficacy in a population of obese/overweight patients. Patients and methods We …

Aims We conducted a systematic review and meta-analysis on three outcomes. We
assessed the efficacy and safety of direct oral anticoagulants (DOAC) compared to vitamin K …

Background: Atrial fibrillation (AF) and obesity are common conditions globally; yet, there
remains suboptimal pharmacological management contributing to high rates of …

Oral anticoagulation is obligatory in patients with atrial fibrillation (AF) to prevent
thromboembolic stroke. Direct direct oral anticoagulants (DOAC) exhibit improved safety …

Highlights•Obesity is an important risk factor for atrial fibrillation.•Despite “obesity paradox”
in atrial fibrillation, patient weight loss preferred.•Oral anticoagulants may be more …